BX471: a CCR1 antagonist with anti-inflammatory activity in man.
Chemokines belong to a large family of chemoattractant molecules involved in the directed migration of immune cells. They achieve their cellular effects by direct interaction with cell surface receptors. The chemokine receptor CCR1 appears to be involved in a variety of proinflammatory and autoimmune diseases and this makes it a very attractive therapeutic target. This review discusses the identification, chemistry, biology and therapeutic potential of BX 471 a potent CCR1 antagonist that is currently in the clinic for a variety of indications.
Horuk
Richard
R
Department of Immunology, Berlex Biosciences, Richmond, CA 94804, USA. Richard_Horuk@Berlex.com.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000378:metabolism; D010671:Phenylurea Compounds / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D010880:Piperidines / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011565:Psoriasis / Q000188:drug therapy / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D010671:Phenylurea Compounds; D010880:Piperidines; C071570:SNF1-related protein kinases; D017346:Protein Serine-Threonine Kinases; C411885:BX 471